Nelivaptan (INN)[1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype.

[2] The drug had entered clinical trials for treatment of anxiety and depression.

[3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.

This hormonal preparation article is a stub.

You can help Wikipedia by expanding it.